<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190566</url>
  </required_header>
  <id_info>
    <org_study_id>PET-MR Breast Cancer</org_study_id>
    <nct_id>NCT01190566</nct_id>
  </id_info>
  <brief_title>PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer</brief_title>
  <official_title>PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

      To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging
      in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced
      breast cancer patients.

      To identify the optimal combination parameters of MR spectroscopy, diffusion-weighted MRI,
      dynamic contrast-enhanced MRI, FDG-PET, and RGD-PET in the prediction and monitoring response
      to neoadjuvant chemotherapy of locally advanced breast cancer patients.

      To compare the performances of dynamic contrast-enhanced MRI using parametric response map
      analysis versus those of pharmacokinetic parameters (Ktrans, kep, or Ve) in the early
      prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled women with breast cancers who had received an anthracycline-taxane regimen and
      subsequent surgery were prospectively enrolled. DCE-MRI and FDG-PET scan were performed
      before and after the 1st cycle of chemotherapy. MR imaging parameters and SUV on PET scan
      within a tumor were analyzed. Clinicopathologic (age, clinical tumor stage, hormonal receptor
      status, and surgery type) and imaging parameters were compared according to the pathological
      response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patholocial Response to Chemotherapy</measure>
    <time_frame>Post-operation</time_frame>
    <description>Pathological complete response (pCR) or non-pCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Size</measure>
    <time_frame>baseline, completion of 1st cycle of chemotherapy</time_frame>
    <description>Maximal tumor diameter measured on magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Volume</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
    <description>Tumor volume measured on 3-dimensional magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Voxels Within a Tumor With Increased or Decreased Signal Intensity (Parametric Response Map Signal Intensity; PRMSI)</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
    <description>Parametric response map analysis using a software calculates the interval change of signal intensity based on a voxel-to-voxel comparison between measurements at baseline and after the first cycle of chemotherapy. PRMSI+ indicates proportions of voxels within a tumor with increased signal intensity. PRMSI- indicates proportions of voxels within a tumor with decreased signal intensity. PRMSI0 indicates proportions of voxels within a tumor with unchanged signal intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constant for the Transfer of the Contrast Agent From the Plasma Compartment Into the Extracellular Extravascular Space (Ktrans)</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate Constant of the Escape of the Contrast Agent From the Extracellular Extravascular Space Into the Plasma Compartment (Kep)</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular Extravascular Space Per Unit Volume of Tissue (Ve)</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Choline Amount of the Tumor Measured on Single Voxel 1H-magnetic Resonance Spectroscopy</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
    <description>Single voxel 1H-magnetic resonance spectroscopy quantifies the amount of total choline-containing compounds of a tumor, which indicates cellular proliferation and malignant transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Uptake Value on 18F-fluoro-deoxy-glucose Positron Emission Tomography</measure>
    <time_frame>Baseline, post-1st chemotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">57</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Core biopsy specimens of breast cancer
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients who are candidates for neoadjuvant chemotherapy, pre-treatment MRI
        and PET scan, post-treatment MRI and PET scan for evaluation of chemotherapy response
        monitoring and residual disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed breast cancer

          -  Clinical stage IIb, IIIa, IIIb, IIIc

          -  Must have measurable disease

          -  Performance status of ECOG 0-2

          -  Adequate, bone marrow, liver, heart, and renal function

          -  Who did not receive chemotherapy for breast cancer

          -  Must agree with and signed informed consent

        Exclusion Criteria:

          -  Prior history of cancer besides breast cancer

          -  Active bacterial infection

          -  Pregnant or lactating women

          -  Psychological disease or seizure

          -  History of arrhythmia, congestive heart failure, myocardial infarct, or unstable
             angina

          -  Male breast cancer

          -  Who had a pacemaker or history of open heart surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Kyung Moon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiology, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://bri.snuh.org/pub/_/singlecont/view.do</url>
    <description>Homepage of Seoul National University Hospital Biomedical Research Institute</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <results_first_submitted>December 30, 2013</results_first_submitted>
  <results_first_submitted_qc>June 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2015</results_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Woo Kyung Moon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging, Functional</keyword>
  <keyword>Tomography, Positron-Emission</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pathologic Complete Responders (pCR)</title>
          <description>The absence of invasive tumor cells (ductal carcinoma in situ may have been present) after surgery.</description>
        </group>
        <group group_id="P2">
          <title>Non-pCR</title>
          <description>The presence of invasive tumor cells (ductal carcinoma in situ may have been present) after surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pathologic Complete Responders (pCR)</title>
          <description>The absence of invasive tumor cells (ductal carcinoma in situ may have been present) after surgery.</description>
        </group>
        <group group_id="B2">
          <title>Non-pCR</title>
          <description>The presence of invasive tumor cells (ductal carcinoma in situ may have been present) after surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>40 years old or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>more than 40 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical stage (American Joint Committee on Cancer 7th edition)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estrogen receptor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Progesterone receptor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HER2</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ki-67 (Cellular marker for proliferation)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>14% or less (low proliferation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>more than 14% (high proliferation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunohistochemical subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hormone receptor positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triple negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patholocial Response to Chemotherapy</title>
        <description>Pathological complete response (pCR) or non-pCR</description>
        <time_frame>Post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Response to Chemotherapy</title>
            <description>Degree of pathologic response to the neoadjuvant chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Patholocial Response to Chemotherapy</title>
          <description>Pathological complete response (pCR) or non-pCR</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pathologic completer Responders (pCR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-pCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Size</title>
        <description>Maximal tumor diameter measured on magnetic resonance imaging</description>
        <time_frame>baseline, completion of 1st cycle of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Size</title>
          <description>Maximal tumor diameter measured on magnetic resonance imaging</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline tumor size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.8"/>
                    <measurement group_id="O2" value="5.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy tumor size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.8"/>
                    <measurement group_id="O2" value="4.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Volume</title>
        <description>Tumor volume measured on 3-dimensional magnetic resonance imaging</description>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Volume</title>
          <description>Tumor volume measured on 3-dimensional magnetic resonance imaging</description>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="18.7"/>
                    <measurement group_id="O2" value="38.9" spread="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="13.2"/>
                    <measurement group_id="O2" value="26.4" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Voxels Within a Tumor With Increased or Decreased Signal Intensity (Parametric Response Map Signal Intensity; PRMSI)</title>
        <description>Parametric response map analysis using a software calculates the interval change of signal intensity based on a voxel-to-voxel comparison between measurements at baseline and after the first cycle of chemotherapy. PRMSI+ indicates proportions of voxels within a tumor with increased signal intensity. PRMSI- indicates proportions of voxels within a tumor with decreased signal intensity. PRMSI0 indicates proportions of voxels within a tumor with unchanged signal intensity.</description>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Voxels Within a Tumor With Increased or Decreased Signal Intensity (Parametric Response Map Signal Intensity; PRMSI)</title>
          <description>Parametric response map analysis using a software calculates the interval change of signal intensity based on a voxel-to-voxel comparison between measurements at baseline and after the first cycle of chemotherapy. PRMSI+ indicates proportions of voxels within a tumor with increased signal intensity. PRMSI- indicates proportions of voxels within a tumor with decreased signal intensity. PRMSI0 indicates proportions of voxels within a tumor with unchanged signal intensity.</description>
          <units>% of voxels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRMSI+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="6.5"/>
                    <measurement group_id="O2" value="40.7" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRMSI-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" spread="7.6"/>
                    <measurement group_id="O2" value="56.4" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRMSI0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="2.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Constant for the Transfer of the Contrast Agent From the Plasma Compartment Into the Extracellular Extravascular Space (Ktrans)</title>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Constant for the Transfer of the Contrast Agent From the Plasma Compartment Into the Extracellular Extravascular Space (Ktrans)</title>
          <units>min-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Ktrans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.263" spread="0.044"/>
                    <measurement group_id="O2" value="0.254" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy Ktrans</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.224" spread="0.076"/>
                    <measurement group_id="O2" value="0.234" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate Constant of the Escape of the Contrast Agent From the Extracellular Extravascular Space Into the Plasma Compartment (Kep)</title>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Rate Constant of the Escape of the Contrast Agent From the Extracellular Extravascular Space Into the Plasma Compartment (Kep)</title>
          <units>min-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.616" spread="0.262"/>
                    <measurement group_id="O2" value="0.787" spread="0.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.992" spread="0.917"/>
                    <measurement group_id="O2" value="0.616" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extracellular Extravascular Space Per Unit Volume of Tissue (Ve)</title>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Extracellular Extravascular Space Per Unit Volume of Tissue (Ve)</title>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.563" spread="0.129"/>
                    <measurement group_id="O2" value="0.550" spread="0.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.467" spread="0.151"/>
                    <measurement group_id="O2" value="0.557" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Choline Amount of the Tumor Measured on Single Voxel 1H-magnetic Resonance Spectroscopy</title>
        <description>Single voxel 1H-magnetic resonance spectroscopy quantifies the amount of total choline-containing compounds of a tumor, which indicates cellular proliferation and malignant transformation.</description>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <population>Of the 48 participants, 13 participants did not undergo magnetic resonance spectroscopy examinations due to workflow problem. We included the available data from 35 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Total Choline Amount of the Tumor Measured on Single Voxel 1H-magnetic Resonance Spectroscopy</title>
          <description>Single voxel 1H-magnetic resonance spectroscopy quantifies the amount of total choline-containing compounds of a tumor, which indicates cellular proliferation and malignant transformation.</description>
          <population>Of the 48 participants, 13 participants did not undergo magnetic resonance spectroscopy examinations due to workflow problem. We included the available data from 35 participants.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="8.4"/>
                    <measurement group_id="O2" value="13.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.8"/>
                    <measurement group_id="O2" value="7.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Uptake Value on 18F-fluoro-deoxy-glucose Positron Emission Tomography</title>
        <time_frame>Baseline, post-1st chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pathologic Complete Responders (pCR)</title>
            <description>the absence of invasive tumor cells after surgery</description>
          </group>
          <group group_id="O2">
            <title>Non-pCR</title>
            <description>the presence of invasive tumor cells after surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Uptake Value on 18F-fluoro-deoxy-glucose Positron Emission Tomography</title>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="12.1"/>
                    <measurement group_id="O2" value="10.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-1st chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="10.7"/>
                    <measurement group_id="O2" value="7.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline, post-1st chemotherapy, preoperative timing</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pathologic Complete Responders (pCR)</title>
          <description>the absence of invasive tumor cells after surgery</description>
        </group>
        <group group_id="E2">
          <title>Non-pCR</title>
          <description>the presence of invasive tumor cells after surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Woo Kyung Moon</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>82-2-2072-2584</phone>
      <email>moonwk@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

